R Velasco1,2, A A Argyriou3, C Marco4, S Mariotto5, A Stradella6, J Hernández7, S Pernas6, S Ferrari5, J Bruna4,7. 1. Unit of Neuro-Oncology, Hospital Universitari de Bellvitge. Catalan Institute of Oncology-L'Hospitalet, Carrer de La Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. rvelascof@bellvitgehospital.cat. 2. Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Universitat Autònoma de Barcelona, Bellaterra, Spain. rvelascof@bellvitgehospital.cat. 3. Neurology Department, Agios Andreas General Hospital of Patras, Patras, Greece. 4. Unit of Neuro-Oncology, Hospital Universitari de Bellvitge. Catalan Institute of Oncology-L'Hospitalet, Carrer de La Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. 5. Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. 6. Department of Medical Oncology, Breast Cancer Unit, ICO L'Hospitalet (IDIBELL), Barcelona, Spain. 7. Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Abstract
INTRODUCTION: Paclitaxel-induced peripheral neurotoxicity (PIPN) typically manifests as a predominantly sensory axonopathy. Nerve conduction studies (NCS) represent the gold standard method to quantify axonal impairment in PIPN. Serum neurofilament light chain (sNfL) levels are emerging biomarkers for quantifying axonal damage in peripheral neuropathies. To date, the association between NCS abnormalities and sNfL levels during paclitaxel-based chemotherapy has not been specifically addressed. METHODS: We prospectively conducted longitudinal measurement of sNfL levels in 27 chemotherapy-naïve breast cancer patients and correlated conventional NCS recordings with sNfL in 22 of them, before (T0) and after (T1) 12 cycles of weekly paclitaxel-based therapy. RESULTS: PIPN was diagnosed in 24/27 patients (88%) after completion of the 12-week paclitaxel-based chemotherapy regimen. Serum NfL levels (pg/mL) were significantly higher at T1 compared to T0 (T0: 18.50 ± 12.88 vs T1: 255.80 ± 194.16; p < 0.001). The increase of sNfL levels at T1 significantly correlated with the decrease or abolishment of amplitudes recorded from the sural nerve (r = 0.620; p = 0.0035), sensory radial (r = 0.613; p = 0.005), sensory ulnar (r = 0.630; p = 0.005), and peroneal motor (r = 0.568; p = 0.024) nerves. CONCLUSION: sNfL levels proportionally increase during chemotherapy administration and significantly correlate with NCS axonal abnormalities in patients with PIPN. A multimodal testing approach employing both sNfL and NCS might improve the PIPN diagnostic accuracy.
INTRODUCTION: Paclitaxel-induced peripheral neurotoxicity (PIPN) typically manifests as a predominantly sensory axonopathy. Nerve conduction studies (NCS) represent the gold standard method to quantify axonal impairment in PIPN. Serum neurofilament light chain (sNfL) levels are emerging biomarkers for quantifying axonal damage in peripheral neuropathies. To date, the association between NCS abnormalities and sNfL levels during paclitaxel-based chemotherapy has not been specifically addressed. METHODS: We prospectively conducted longitudinal measurement of sNfL levels in 27 chemotherapy-naïve breast cancer patients and correlated conventional NCS recordings with sNfL in 22 of them, before (T0) and after (T1) 12 cycles of weekly paclitaxel-based therapy. RESULTS: PIPN was diagnosed in 24/27 patients (88%) after completion of the 12-week paclitaxel-based chemotherapy regimen. Serum NfL levels (pg/mL) were significantly higher at T1 compared to T0 (T0: 18.50 ± 12.88 vs T1: 255.80 ± 194.16; p < 0.001). The increase of sNfL levels at T1 significantly correlated with the decrease or abolishment of amplitudes recorded from the sural nerve (r = 0.620; p = 0.0035), sensory radial (r = 0.613; p = 0.005), sensory ulnar (r = 0.630; p = 0.005), and peroneal motor (r = 0.568; p = 0.024) nerves. CONCLUSION: sNfL levels proportionally increase during chemotherapy administration and significantly correlate with NCS axonal abnormalities in patients with PIPN. A multimodal testing approach employing both sNfL and NCS might improve the PIPN diagnostic accuracy.
Authors: Lorenzo Gaetani; Kaj Blennow; Paolo Calabresi; Massimiliano Di Filippo; Lucilla Parnetti; Henrik Zetterberg Journal: J Neurol Neurosurg Psychiatry Date: 2019-04-09 Impact factor: 10.154
Authors: Åsa Sandelius; Henrik Zetterberg; Kaj Blennow; Rocco Adiutori; Andrea Malaspina; Matilde Laura; Mary M Reilly; Alexander M Rossor Journal: Neurology Date: 2018-01-10 Impact factor: 9.910
Authors: Su-Hyun Kim; Moon Ki Choi; Na Young Park; Jae-Won Hyun; Min Young Lee; Ho Jin Kim; Su Kyung Jung; Yongjun Cha Journal: Sci Rep Date: 2020-05-14 Impact factor: 4.379
Authors: Luuk Wieske; Duncan Smyth; Michael P Lunn; Filip Eftimov; Charlotte E Teunissen Journal: Neurotherapeutics Date: 2021-10-18 Impact factor: 7.620
Authors: Petra Huehnchen; Christian Schinke; Nikola Bangemann; Adam D Dordevic; Johannes Kern; Smilla K Maierhof; Lois Hew; Luca Nolte; Peter Körtvelyessy; Jens C Göpfert; Klemens Ruprecht; Christopher J Somps; Jens-Uwe Blohmer; Jalid Sehouli; Matthias Endres; Wolfgang Boehmerle Journal: JCI Insight Date: 2022-03-22